| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Barr Pharmaceuticals is one of the USA's leading generic manufacturers. The
company has a policy of early market entry for generics, and as such is
generally involved in a large amount of litigation. This report provides an
insight into the company, reviewing its current business structure and
activities.
Barr Pharmaceuticals is a holding company that operates through its principal
subsidiaries, Barr Laboratories and Duramed Pharmaceuticals. The company is
engaged in the development, manufacture and marketing of generic and
proprietary pharmaceuticals. In January 2004, the company was reincorporated
in Delaware as Barr Pharmaceuticals; Barr Laboratories, Duramed
Pharmaceuticals and Duramed Research were established as subsidiaries.
Barr was founded in New York in 1970, making it one of the oldest generic
pharmaceutical manufacturers in the United States. The company's first
products, antibiotics manufactured under contract for other pharmaceutical
companies, were launched in 1972. However, Barr did not really begin to
develop until after the implementation of the Hatch-Waxman Act in 1984, which
set the scope for the generic industry in the US. Barr focuses on three
strategies:
- Development and marketing of select generic products
- Development and introduction of proprietary medicines
- Challenging patents protecting selected branded products
Barr currently employs around 1,900 personnel, and has operations in New York,
New Jersey, Ohio, Pennsylvania, Washington, DC, and Virginia.
This report provides information on the company's active product lines and
ANDA approvals, along with a review of major developments, such as M&A
activity, strategic alliances and litigation. The company's most recent
quarterly and annual financial results are illustrated with comparative
figures, charts and a detailed review of the data which allows you to track
the company's progress.
TABLE OF CONTENTS
- EXECUTIVE SUMMARY
- INTRODUCTION
- PRODUCTS
- Barr Laboratories ANDA Approvals, 2002-05
- Recent product approvals
- Zonisamide
- Leflunomide tablets
- Clonazepam
- Fexofenadine capsules
- Kelnor OC generic
- Generic Allegra-D 12 Hour Extended-Release tablets
- Niacin ER tablets
- Anagrelide capsules
- Mirtazapine (tentative)
- FINANCIAL RESULTS
- Latest Full Year Highlights
- Full Year Results, 2001-05
- Segment Data
- Segment Results, 2003-05
- Latest Quarterly Results, second quarter ended 31st December 2005
- MAJOR DEVELOPMENTS
- Mergers, acquisitions and agreements .
- Barr/Pliva sign agreement to develop and market generic version of
G-CSF in US and Canada
- Barr gains generic fentanyl agreement
- Barr and Galen complete agreements
- Enhance Pharmaceuticals
- Wyeth
- Endeavor Pharmaceuticals
- Women's Capital Corporation
- Litigation
- Barr enters patent litigation settlement agreements with Cephalon
- FTC files amicus brief in tamoxifen antitrust litigation
- FTC sues over Ovcon agreement
- Johnson & Johnson launches suit over Razadyne (formerly Reminyl)
- Shire Pharmaceuticals, Adderall XR
- Schering files patent infringement lawsuit against Barr
- Barr withdraws challenge to FDA's exclusivity policy
- Kos and Barr settle lawsuits, sign agreements for Niaspan products
- Barr granted summary judgement on additional patent in Allegra patent
challenge
- Court rejects challenge to lawfulness of Barr's Cipro settlement with
Bayer
- Desmopressin
- CONTACT DETAILS
|
